BMS nabs hep c partner Zymogenetics for $885M; Sun prevails in Taro's court challenge;

@FiercePharma: Weldon: J&J's recall probe almost wrapped. Article | Follow @FiercePharma

> Bristol-Myers Squibb agreed to acquire ZymoGenetics, the maker of a hepatitis C drug the companies were jointly developing, for $885 million. News

> India's Sun Pharmaceutical Industries took a big leap towards taking control of Israel's Taro Pharmaceutical Industries. Report

> Use of biomarkers in clinical trials to grow at blistering pace. News

> Allergan directors should be held liable for opening up the maker of wrinkle smoother Botox to criminal sanctions and a $600 million settlement by allowing the drug to be marketed for unapproved uses, investors said in a lawsuit. Article

> Biomarker helps guide study on smoking cessation treatments. Report

> Researchers' biomarker discovery could help those with Alzheimer's. Item

> Standard & Poor's Ratings Services may cut its credit ratings on Sanofi-Aventis, which is trying to buy the biotechnology company Genzyme. Article

> Merck's antipsychotic drug Saphris won the FDA nod for two additional uses: ongoing schizophrenia treatment and as an add-on to bipolar standbys lithium and valproate. Item

> Purdue Pharma has agreed to pay $16 million to settle a lawsuit by purchasers of Oxycontin over how it obtained patents on the painkiller in the 1990s. Story

> Lonza said it would manufacture a number of drug compounds for GlaxoSmithKline, adding to signs of a revival in demand from pharmaceutical clients. Report

> More than 80 percent of U.K. pharmacists say it is now more difficult than ever to obtain branded medicines and many expect things to get worse next year, a new survey shows. News

Biotech News

 @FierceBiotech: Actavis eyes fast-growing biosimilar market. News | Follow @FierceBiotech

 @JohnCFierce:  Biovail, Valeant plan to cut 25% of combined staffs. Get the impression from Reuters that R&D is getting downplayed. Article | Follow @JohnCFierce

> Zogenix files for $90 million IPO. Report

> Third Rock pushes Rhythm venture round to $40 million. News

> Onyx snags $339 million Japan deal for PhIII cancer med. Article

Medical Device News

> St. Jude invests $60M in CardioMEMS. Report

> Garrett resigns as Beckman Coulter CEO. News

> Sicel names McDaniel interim president, avoids bankruptcy. Item

> Invacare asks ITC to exclude beds. Story

Drug Delivery News

> FDA OKs thin-film version of opioid-dependence drug. Report

> BDSI, Meda, FDA talk about streamlining REMS for Onsolis. Story

> SHL says "Good Golly" to "Molly" in syringe marketing campaign. Article

> Alexza licenses Staccato nicotine delvery to Cypress Bioscience. Item

And Finally... Israeli scientists found a significant link between taking cholesterol-lowering statin drugs like Pfizer's Lipitor or AstraZeneca's Crestor and a reduced risk of developing rheumatoid arthritis. Article

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.